NCT00054535View on ClinicalTrials.gov

Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

January 31, 2003

Study Completion Date

September 30, 2004

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

aldesleukin

BIOLOGICAL

recombinant fowlpox-tyrosinase vaccine

BIOLOGICAL

vaccinia-tyrosinase vaccine

Trial Locations (1)

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00054535 - Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter